A051701: Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas (clinicaltrials.gov) - Oct 20, 2026 - P2/3 | N=363 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Apr 2028 ➔ Aug 2028 | Trial primary completion date: Apr 2028 ➔ Aug 2028
Trial completion date • Trial primary completion date • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Indolent Lymphoma • Lymphoma • Non-Hodgkin's Lymphoma • Oncology • BCL2 • BCL6 • MYC
|